Clin2
NCT05959252Possibly a fitRecruiting

Bivalirudin vs heparin for blood thinning during ECMO

Extracorporeal Membrane Oxygenation Complication

Treatments studied

Part of Blood & lymphatic, Heart & circulation clinical trials.

This Phase 2 trial compares two blood-thinning medicines—bivalirudin and heparin—in people on ECMO (a machine that supports breathing and/or circulation). It aims to see which medicine works better and is safer while you are connected to the ECMO circuit.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
80 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are currently receiving ECMO (the life-support machine)
  • You are 18 years or older
  • The study team can randomize you within 4 hours after ECMO is started
  • You are not a “post-cardiotomy” ECMO patient (ECMO started right after heart surgery)
  • You can take either heparin or bivalirudin safely at the time of enrollment (no major active bleeding or known allergy/contraindication)
  • You are not expected to be taken off ECMO within the next day after the tubes are placed

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06275555Recruiting
Bivalirudin for blood thinning in ECMO patients

This trial tests if bivalirudin is a safe and effective blood thinner for people on ECMO, a machine that helps your heart and lungs. You may be eligible if you need this therapy and have no past reactions to similar medicines.

Beijing, Beijing Municipality
NCT04273607Recruiting· Phase 2/Phase 3
Test an ECMO approach without blood thinners for lung failure

This trial studies whether people on a breathing machine called VV-ECMO can be managed without routine blood thinners, to reduce bleeding risk. It is meant for adults with severe lung failure (ARDS) and checks that it is safe for you to avoid anticoagulation.

Toronto, Ontario
NCT06276010Recruiting
Nafamostat mesilate for blood thinning in ECMO patients

This trial tests a medicine called nafamostat mesilate to prevent blood clots in patients who need ECMO (a machine that helps your heart and lungs) after heart surgery. It may offer a safer way to thin the blood compared to standard treatments.

Beijing, Beijing Municipality
NCT07580469Not yet recruiting
Blood Clotting and Heart-Lung Support Machine Study

This study examines how blood clotting cells (platelets) behave when patients are on a heart-lung support machine called ECMO. Researchers will take small blood samples to understand if the machine affects platelet function and how to manage blood thinning medication safely.

Toulouse
NCT06442267Recruiting· Phase 4
Comparing blood thinners for ECMO support

This trial compares three different blood thinners (heparin, argatroban, and enoxaparin) used during ECMO support. It aims to find the safest and most effective way to prevent blood clots while on ECMO.

Vienna, State of Vienna
NCT07499037Not yet recruiting· Phase 2
Low-dose blood thinners for ECMO patients

This trial tests whether low doses of two blood thinners (argatroban and enoxaparin) can safely prevent clots in patients on ECMO life support. It aims to find a safer way to manage anticoagulation.

Ostrava, Moravian-Silesian Region

Hear when a new Extracorporeal Membrane Oxygenation Complication trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.